Abstract
To investigate the efficacy and tolerability of orlistat in obese adolescents, a prospective, open-label, randomised, controlled pilot trial was performed. A total of 22 adolescents with exogeneous obesity were started on orlistat (120 mg tid) and a daily multivitamin preparation in addition to conventional treatment which included nutritional and lifestyle modification programmes. The control group consisted of 20 obese adolescents who had similar duration of follow-up under conventional treatment alone. Of the 22 patients, 7 dropped out within the 1st month of the trial due to side-effects attributable to orlistat. The remaining 15 patients on orlistat were followed for 5–15 months (average duration of treatment 11.7±3.7 months). The control group was similar in age, sex, and duration of follow-up (10.2±3.7 months, range 6–17 months) to the orlistat group. Compared to initial body weight, patients in the orlistat group lost −6.27±5.4 kg, whereas those in the control group gained 4.16±6.45 kg (P<0.001) during the study period. Patients in the orlistat group lost −7.65%±6.5% of their initial body weight, whereas, those of the control group gained 5.7%±8.3% (P<0.001). The body mass index decreased in the orlistat group by −4.09±2.9 kg/m2 while it increased by +0.11±2.49 kg/m2 in the control group (P<0.001). Mild gastrointestinal complaints (frequent stools) were experienced by all patients in the orlistat group. Conclusion:Orlistat could be a useful adjunct in the treatment of severe obesity in adolescents; however, gastrointestinal side-effects limit its usefulness in almost one in three adolescents.
Similar content being viewed by others
Abbreviations
- BMI :
-
body mass index
References
Diamond FB (1998) Newer aspects of the pathophysiology, evaluation, and management of obesity in childhood. Curr Opin Pediatr 10: 422–427
Epstein LH, Myers MD, Raynor HA, Saelens BE (1998) Treatment of pediatric obesity. Pediatrics 101[Suppl]: 554–570
Finer N, James WP, Kopelman PG, Lean ME, Williams G (2000) One year treatment of obesity: a randomized, double-blind, placebo controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Relat Metab Disord 24: 306–313
Kitagawa T, Owada M, Urakami T, Yamauchi K (1998) Increased incidence of non-insulin dependent diabetes mellitus among Japanese schoolchildren correlates with an increased intake of animal protein and fat. Clin Pediatr 37: 111–115
McDuffie JR, Calis KA, Booth SL, Uwaifo GI, Yanovski JA (2002) Effects of orlistat on fat-soluble vitamins in obese adolescents. Pharmacotherapy 22: 814–822
McDuffie JR, Calis KA, Uwaifo GI, Sebring NG, Fallon EM, Hubbard VS, Yanovski JA (2002) Three-month tolerability of orlistat in adolescents with obesity-related comorbid conditions. Obes Res 10: 642–650
McDuffie JR, Calis KA, Uwaifo GI, Sebring NG, Fallon EM, Fraser TE, Van Hubbard VS, Yanovski JA (2004) Efficacy of orlistat as an adjunct to behavioral treatment in overweight African-American and Caucasian adolescents with obesity-related co-morbid conditions. J Pediatr Endocrinol Metab 17: 307–319
Norgren S, Danielsson P, Lötborn M, Jurold R, Marcus C (2003) Orlistat treatment in obese prepubertal children. Acta Paediatr 92: 666–670
Orlistat: a second look. At best, a minor adjunct to dietary measures (2002) Prescribe Int 11: 10–12
Pinelli L, Elerdini N, Faith MS, Agnello D, Ambruzzi A, De Simone M, Leggeri G, Livieri C, Monetti N, Peverelli P, Salvatoni A, Seminara S, Uasone R, Pietrobelli A (1999) Childhood obesity. Results of a multicenter study of obesity treatment in Italy. J Pediatr Endocrinol Metab 12 [Suppl 3]: 795–799
Pinhas-Hamiel O, Dolan LM, Daniels SR, Standiford D, Khoury PR, Zeitler P (1996) Increased incidence of non-insulin dependent diabetes mellitus among adolescents. J Pediatr 128: 608–611
Rossner S, Sjostrom L, Noack R, Meinders AE, Noseda G (2000) Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes Res 8: 49–61
Styne MD (2001) Childhood and adolescent obesity. Prevalence and significance. Pediatr Clin North Am 48: 823–854
Acknowledgements
This work was supported by the Turkish Academy of Sciences within the framework of the Young Scientist Award program (EA/TUBA-GEBIP/2001–1-1).
Author information
Authors and Affiliations
Corresponding author
Additional information
This work was presented in part at the 41st Annual Meeting of the ESPE, Madrid, 2002.
Rights and permissions
About this article
Cite this article
Ozkan, B., Bereket, A., Turan, S. et al. Addition of orlistat to conventional treatment in adolescents with severe obesity. Eur J Pediatr 163, 738–741 (2004). https://doi.org/10.1007/s00431-004-1534-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00431-004-1534-6